Rebamipide
- Generic Name
- Rebamipide
- Drug Type
- Small Molecule
- Chemical Formula
- C19H15ClN2O4
- CAS Number
- 90098-04-7
- Unique Ingredient Identifier
- LR583V32ZR
- Background
Rebamipide has been investigated for the treatment of Stomach Ulcer, Keratoconjunctivitis Sicca, and Gastric Adenoma and Early Gastric Cancer.
- Indication
主要用于胃溃疡，但不宜单独用于Hp感染。也用于改善胃炎及慢性胃炎急性加重期的胃黏膜病变（如糜烂、出血、充血、水肿等）。
- Associated Conditions
- Gastric Ulcer
A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
- First Posted Date
- 2013-03-19
- Last Posted Date
- 2013-03-22
- Lead Sponsor
- Dong-A Pharmaceutical Co., Ltd.
- Target Recruit Count
- 492
- Registration Number
- NCT01813812
- Locations
- 🇰🇷
Seoul National University Hospital, Seoul, Korea, Republic of
Rebamipide AND Sjögren Syndrome
- Conditions
- Improving Symptoms of Dry Mouth in Sjőgren's Syndrome
- Interventions
- First Posted Date
- 2013-01-02
- Last Posted Date
- 2020-03-31
- Lead Sponsor
- University of Alexandria
- Target Recruit Count
- 55
- Registration Number
- NCT01759108
- Locations
- 🇪🇬
Faculty of Medicine, University of Alexandria, Alexandria, Egypt
Confirmatory Study of OPC-12759 Ophthalmic Solution
- First Posted Date
- 2012-08-08
- Last Posted Date
- 2021-05-05
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 209
- Registration Number
- NCT01660256
- Locations
- 🇯🇵
Kansai Region, Kansai Region, Japan
🇯🇵Kanto region, Kanto Region, Japan
🇯🇵Kyushu region, Kyushu Region, Japan
Efficacy and Safety of Rebamipide in Subjects With Dry Eye Syndrome
- Conditions
- Dry Eye Syndrome
- Interventions
- Drug: Placebo (vehicle)
- First Posted Date
- 2012-07-02
- Last Posted Date
- 2014-05-07
- Lead Sponsor
- Kubota Vision Inc.
- Target Recruit Count
- 564
- Registration Number
- NCT01632137
The Pharmacokinetic Interaction Between Celecoxib and Rebamipide
- Conditions
- Healthy Male Volunteers
- Interventions
- First Posted Date
- 2012-03-09
- Last Posted Date
- 2018-08-17
- Lead Sponsor
- Hanlim Pharm. Co., Ltd.
- Target Recruit Count
- 30
- Registration Number
- NCT01549743
- Locations
- 🇰🇷
The Korea Univertisy Anam Hospital, Seoul, Korea, Republic of
Exploratory Study of OPC-12759 Ophthalmic Suspension
- Conditions
- Keratoconjunctival Epithelial Disorder
- Interventions
- First Posted Date
- 2011-12-15
- Last Posted Date
- 2015-03-10
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 102
- Registration Number
- NCT01493180
- Locations
- 🇯🇵
Kansai Region, Kobe, Japan
🇯🇵Chugoku region, Kure, Japan
🇯🇵Tokai region, Nagoya, Japan
Safety Study of OPC-12759 Ophthalmic Solution
- Conditions
- Dry Eye Syndromes
- Interventions
- Drug: OPC-12759 Ophthalmic solution
- First Posted Date
- 2011-11-11
- Last Posted Date
- 2021-06-29
- Lead Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT01471093
- Locations
- 🇯🇵
Kansai region, Osaka, Japan
Is Rebamipide Effective on the Healing of Iatrogenic Gastric Ulcer After Endoscopic Mucosal Resection?
- First Posted Date
- 2010-07-22
- Last Posted Date
- 2015-09-04
- Lead Sponsor
- Kangdong Sacred Heart Hospital
- Target Recruit Count
- 290
- Registration Number
- NCT01167101
- Locations
- 🇰🇷
Kangdong Sacred Heart Hospital, Seoul, Korea, Republic of
Mucosta in Gastric Ulcer Treatment, Effectiveness and Safety Evaluation
- First Posted Date
- 2010-06-24
- Last Posted Date
- 2013-02-04
- Lead Sponsor
- Otsuka Pakistan Limited
- Target Recruit Count
- 129
- Registration Number
- NCT01150162
- Locations
- 🇵🇰
Dr. Ziauddin University Hospital, Karachi, Pakistan
🇵🇰Dow University of Health Sciences, Karachi, Pakistan
🇵🇰Abbasi Shaheed Hospital, Karachi, Pakistan
Safety and Efficacy Study of Rebamipide 2% Ophthalmic Suspension in Subjects With Dry Eye - Effects on Central Cornea
- Conditions
- Keratoconjunctivitis SiccaDry Eye
- Interventions
- Drug: placebo eye drops
- First Posted Date
- 2010-01-27
- Last Posted Date
- 2012-01-11
- Lead Sponsor
- Kubota Vision Inc.
- Target Recruit Count
- 116
- Registration Number
- NCT01057147
- Locations
- 🇺🇸
Macy Eye Center, Los Angeles, California, United States
🇺🇸Cohen Laser and Vision Center, Boca Raton, Florida, United States
🇺🇸East Valley Ophthalmology, Mesa, Arizona, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.